ES2610474T3 - Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia - Google Patents

Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia Download PDF

Info

Publication number
ES2610474T3
ES2610474T3 ES08719192.0T ES08719192T ES2610474T3 ES 2610474 T3 ES2610474 T3 ES 2610474T3 ES 08719192 T ES08719192 T ES 08719192T ES 2610474 T3 ES2610474 T3 ES 2610474T3
Authority
ES
Spain
Prior art keywords
seq
autoantibodies
alzheimer
diagnosis
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08719192.0T
Other languages
English (en)
Spanish (es)
Inventor
Richard Dodel
Michael Bacher
Michael Przybylski
Raluca Stefanescu
Marilena Manea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07000507A external-priority patent/EP1944314A1/en
Priority claimed from EP07000521A external-priority patent/EP1944315A1/en
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2610474T3 publication Critical patent/ES2610474T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES08719192.0T 2007-01-11 2008-01-11 Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia Active ES2610474T3 (es)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US88452607P 2007-01-11 2007-01-11
US88451307P 2007-01-11 2007-01-11
EP07000507A EP1944314A1 (en) 2007-01-11 2007-01-11 Diagnosis of Alzheimer's disease and other neurodementing disorders
US884513P 2007-01-11
EP07000521A EP1944315A1 (en) 2007-01-11 2007-01-11 Prophylaxis and therapy of alzheimer's disease and other neurodementing diseases
EP07000507 2007-01-11
US884526P 2007-01-11
EP07000521 2007-01-11
US98167507P 2007-10-22 2007-10-22
US98166707P 2007-10-22 2007-10-22
EP07119026 2007-10-22
EP07119026 2007-10-22
EP07119002 2007-10-22
EP07119002 2007-10-22
US981675P 2007-10-22
US981667P 2007-10-22
PCT/IB2008/000456 WO2008084402A2 (en) 2007-01-11 2008-01-11 Diagnosis and treatment of alzheimer's and other neurodementing diseases

Publications (1)

Publication Number Publication Date
ES2610474T3 true ES2610474T3 (es) 2017-04-27

Family

ID=39609117

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08719192.0T Active ES2610474T3 (es) 2007-01-11 2008-01-11 Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia

Country Status (11)

Country Link
US (3) US7939075B2 (enExample)
EP (1) EP2104682B1 (enExample)
JP (1) JP2010515717A (enExample)
AU (1) AU2008204335B2 (enExample)
CA (1) CA2675340C (enExample)
DK (1) DK2104682T3 (enExample)
ES (1) ES2610474T3 (enExample)
PL (1) PL2104682T3 (enExample)
SI (1) SI2104682T1 (enExample)
TW (1) TW200844110A (enExample)
WO (1) WO2008084402A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2143447A1 (en) * 2008-07-11 2010-01-13 Universität Konstanz Bioconjugates comprising Aß-autoantibody-specific epitopes for active immunotherapy and diagnosis of Alzheimer's disease
DK3395372T3 (da) * 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
KR101095630B1 (ko) * 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제
DE102009034119A1 (de) * 2009-07-20 2011-01-27 Philipps-Universität Marburg Verfahren, insbesondere Enzyme-linked Immunosorbent Assay (ELISA), zum in vitro Nachweis von Amyloid beta Autoantikörpern, Mikrotiterplatte und Testkit
WO2011017600A2 (en) 2009-08-07 2011-02-10 American Life Science Pharmaceuticals, Inc. (Alsp Inc.) Compositions and methods for treating beta-amyloid related diseases
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
DK2579042T3 (da) * 2011-10-04 2014-07-21 Affiris Ag Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
KR101190573B1 (ko) * 2011-10-07 2012-10-18 대한민국 혈액 내 아밀로이드-베타 항체에 특이적으로 결합하는 신규 Ａβ２２（ｐＥ）－４２ 펩티드를 유효성분으로 포함하는 치매 진단용 키트
US20130273574A1 (en) * 2012-03-13 2013-10-17 Janssen Alzheimer Immunotherapy Oligomeric a-beta in the diagnosis, prognosis, and monitoring of alzheimer's disease
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
JP6582995B2 (ja) * 2014-01-21 2019-10-02 株式会社島津製作所 Ａｐｐ切断型ペプチドの測定方法
US11073470B2 (en) * 2014-02-14 2021-07-27 Betasense Gmbh Attenuated total reflectance-based biosensor for conformation and secondary structure analysis
US10035823B2 (en) 2014-09-29 2018-07-31 The Regents Of The University Of California Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
ES2663623T3 (es) * 2015-01-12 2018-04-16 Heraeus Deutschland GmbH & Co. KG Uso de una composición eléctricamente conductora como adhesivo eléctricamente conductor para conectar mecánica y eléctricamente conductores eléctricos con los contactos eléctricos de células solares
ES2834484T3 (es) 2016-11-21 2021-06-17 Univ Ruhr Bochum Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US11773171B2 (en) * 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
CA3085596A1 (en) * 2017-12-19 2019-06-27 Surrozen, Inc. Anti-frizzled antibodies and methods of use
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
WO1994017197A1 (fr) 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP2305709A1 (en) 1997-04-09 2011-04-06 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
JP4804690B2 (ja) 1999-12-08 2011-11-02 インテレクト・ニューロサイエンシズ・インコーポレーテッド 免疫原としてのキメラペプチド、それに対する抗体、およびキメラペプチドまたは抗体を用いた免疫法
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
KR100767146B1 (ko) 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
US20030083277A1 (en) 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
EP2275449B1 (en) * 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US20050208050A1 (en) * 2001-11-09 2005-09-22 Gerd Multhaup Compounds for the diagnosis/prevention/treatment of alzheimer's disease
US20050227941A1 (en) 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
EP1578361B1 (en) 2002-09-12 2011-04-20 The Regents of The University of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
AU2003279728B2 (en) 2002-10-01 2007-09-27 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
MXPA05003621A (es) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
US20050106626A1 (en) 2002-10-20 2005-05-19 George Pieczenik Ligand binding of amyloid peptide protein epitope
EA013677B1 (ru) * 2002-11-15 2010-06-30 Генмаб А/С Человеческие моноклональные антитела против cd25 и их применение
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
JP2007527865A (ja) 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
AR047729A1 (es) * 2003-11-28 2006-02-15 Astrazeneca Ab Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
AU2005217596B2 (en) 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2006017173A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
WO2006055178A2 (en) 2004-10-25 2006-05-26 Merck & Co., Inc. Anti-addl antibodies and uses thereof
WO2006066171A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
HRP20110859T1 (hr) * 2004-12-21 2011-12-31 Medimmune Limited Protutijela usmjerena na angiopoietin-2 i njihova upotreba
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
CA2595380A1 (en) 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US9133267B2 (en) 2005-11-22 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody treatment of Alzheimer's and related diseases
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
JP5419131B2 (ja) 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ１〜４２特異的モノクローナル抗体
BRPI0709050B1 (pt) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
JP2010516651A (ja) * 2007-01-17 2010-05-20 メルク セローノ ソシエテ アノニム Ｆｃ含有タンパク質の精製のための方法
CA2714413C (en) * 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof

Also Published As

Publication number Publication date
SI2104682T1 (sl) 2017-05-31
US20120040382A1 (en) 2012-02-16
WO2008084402A3 (en) 2009-04-09
AU2008204335B2 (en) 2013-06-13
CA2675340C (en) 2018-07-31
EP2104682A2 (en) 2009-09-30
US7939075B2 (en) 2011-05-10
CA2675340A1 (en) 2008-07-17
EP2104682B1 (en) 2016-09-21
US20090028869A1 (en) 2009-01-29
JP2010515717A (ja) 2010-05-13
US20120039897A1 (en) 2012-02-16
AU2008204335A1 (en) 2008-07-17
PL2104682T3 (pl) 2017-03-31
WO2008084402A2 (en) 2008-07-17
TW200844110A (en) 2008-11-16
DK2104682T3 (en) 2017-01-16
WO2008084402A8 (en) 2009-08-27
US8491903B2 (en) 2013-07-23

Similar Documents

Publication Publication Date Title
ES2610474T3 (es) Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
US12129289B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
US20210206843A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
ES2616961T3 (es) Composición de anticuerpos pan-HER
US20240309077A1 (en) Anti-apoe antibodies
UA90846C2 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Ab)
JP2018531580A5 (enExample)
KR20130135931A (ko) 아밀로이드 펩티드를 측정하기 위한 항체, 키트 및 방법
US20140241987A1 (en) Alpha-synuclein antibodies and uses thereof
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
Mougenot et al. Production of a monoclonal antibody, against human α-synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the α-synuclein locus
Rábano et al. Diversity of senile plaques in Alzheimer's disease as revealed by a new monoclonal antibody that recognizes an internal sequence of the Aβ peptide
EP3126839B1 (en) Agents useful in diagnostic and therapy of beta-amyloid aggregation related disorders and screening methods
OA18779A (en) Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof.
Lachmann et al. New monoclonal antibody 5G4 suitable for specific detection of disease-associated α-synuclein in the human brain
HK40007700B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof